Lactiga is a venture-backed, NIH-funded biotherapeutics company developing patented biologics to treat and prevent mucosal infections with a focus on improving the quality of life in patients with Primary Immunodeficiency Diseases. They are unlocking the full therapeutic value of human milk antibodies to create the next-generation of anti-infectives that can battle even the world’s most dangerous pathogens including Covid. Lactiga has earned multiple awards, media attention (Globe & Mail, CTV, Toronto Star) and is participating in the On Deck Health (ODH2) cohort.
AngelMD Profile: https://www.angelmd.co/en/startups/lactiga
Torque3 is developing a neurorehabilitation solution that has shown in early testing to result in significantly better recovery outcomes. A wealth of research over...
Eyetamins is a healthcare technology and life sciences company focused on therapeutics and consumer innovations in the $200B eye health and wellness space. They...
NXgenPort (NGP), has designed an innovative and transformative technology to maximize remote care in cancer patients requiring an implantable chemo-port catheter. Combining proven chemo-port...
